Real-world evidence of reported symptoms and quality of life burden associated with chronic rhinosinusitis with nasal polyposis and comorbid asthma status Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021
Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Sleep problems and quality of life in nasal polyposis Source: Eur Respir J 2003; 22: Suppl. 45, 116s Year: 2003
Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP) Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018
Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Treatment of nasal polyposis in aspirine sensitive asthma Source: Eur Respir J 2001; 18: Suppl. 33, 425s Year: 2001
Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
The clinical relationship of nasal polyposis to asthma and other pathologies in the French population Source: Eur Respir J 2003; 22: Suppl. 45, 114s Year: 2003
Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma Source: International Congress 2017 – Management of asthma in different situations Year: 2017
Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017
Quality of life, clinical symptoms and nasal obstruction in patients with allergic rhinitis Source: Eur Respir J 2003; 22: Suppl. 45, 418s Year: 2003
Effectiveness of omalizumab in improving quality of life in patients with ‘steroid-resistant‘ asthma and severe allergic rhinitis Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
Rhinitis, nasosinusal polyposis and asthma: clinical aspects Source: ISSN=1025-448x, ISBN=1-904097-19-17, page=101 Year: 2001
Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Benralizumab effectiveness on quality of life of severe eosinophilic asthmatics in real life Source: Virtual Congress 2020 – Investigations of COPD Year: 2020
Aspirin-induced urticaria/angioedema without respiratory symptoms in severe asthmatics with nasal polyposis Source: Eur Respir J 2002; 20: Suppl. 38, 512s Year: 2002
Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: Results from a phase 2a trial Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016
Patients with asthma and comorbid allergic rhinitis: Is optimal quality of life achievable in real life? Source: Annual Congress 2011 - Asthma: risk factors and comorbidities Year: 2011